uniQure N.V, Bristol-Myers deal
uniQure granted Bristol-Myers exclusive access to uniQure’s gene therapy technology platform for multiple disease targets. The deal includes AAV-S100A1, an adeno-associated virus (AAV) vector expressing S100 calcium binding protein A1 (S100A1). The compound is in preclinical testing to treat congestive heart failure by restoring the heart’s ability to synthesize S100A1, a calcium sensor and master regulator of heart function. uniQure expects clinical testing to start in 2017. The deal also includes the potential for target-exclusive collaboration in other cardiovascular and non-cardiovascular diseases on nine targets, excluding S100A1.
uniQure is responsible for lead discovery, manufacturing of clinical and commercial supplies using its vector technologies and its industrial, insect cell-based manufacturing platform. BMS is responsible for lead development, regulatory activities, R&D costs and commercialization. ...